US withdrawal from Iran deal can hit Danish companies

The US's withdrawal from the Joint Plan of Action with Iran and the reimposition of sanctions can impact Danish pharmaceutical companies and medico firms, writes the Danish interest group Dansk Industri. Novo Nordisk, which has invested DKK 500 million (EUR 67 million) in Iran, awaits further developments.

Iranians protested on Friday after US President Trump decided to withdraw from the Joint Comprehensive Plan of Action and reimposed sanctions. Photo: /Ritzau Scanpix/AFP/STR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

David Solomon lander nyt topjob

Mindre end tre måneder efter at være trådt tilbage som adm. direktør i amerikansk biotekselskab efter kontrovers om brug af et kreditkort er den tidligere Zealand Pharma-topchef David Solomon atter tilbage i direktørstolen. Denne gang i et britisk biotekselskab.

Related articles